Table 2.
Quantitative determination of NYS and MET in Amrizole N® vaginal suppository and NYS and MIC in Monicure plus® vaginal suppository by the proposed HPLC and HPTLC methods and application of standard addition technique
| Pharmaceutical formulation | Drug | HPLC | HPTLC | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Taken (μg/mL) |
Founda % ± SD | Pure added (μg/mL) |
%Recoveryb | Taken (μg/band) |
Founda % ± SD | Pure added (μg/band) | %Recoveryb | ||
|
Amrizole N® vaginal suppository Batch NO. (977,243) |
NYS | 40.00 | 0.57 ± 99.08 | 3.00 | 99.27 | 1.00 | 0.86 ± 99.11 | 0.60 | 100.00 |
| 6.00 | 98.42 | 0.80 | 101.11 | ||||||
| 9.00 | 98.96 | 1.00 | 99.60 | ||||||
| SD ± Mean | 98.88 ± 0.43 | SD ± Mean | 0.78 ± 100.24 | ||||||
| MET | 12.00 |
± 102.55 0.44 |
6.00 | 98.39 | 1.00 |
± 102.32 0.27 |
0.50 | 99.94 | |
| 12.00 | 98.31 | 0.60 | 100.50 | ||||||
| 18.00 | 98.52 | 1.00 | 98.96 | ||||||
| SD ± Mean | 0.11 ± 98.41 | SD ± Mean | 0.78 ± 99.80 | ||||||
|
Monicure plus® vaginal suppository Batch NO. (7,373,004) |
NYS | 40.00 |
± 101.28 0.66 |
3.00 | 100.87 | 1.00 |
± 101.03 0.44 |
0.60 | 100.00 |
| 6.00 | 100.13 | 0.80 | 100.38 | ||||||
| 9.00 | 100.40 | 1.00 | 100.16 | ||||||
| SD ± Mean | 0.38 ± 100.47 | SD ± Mean | 0.19 ± 100.18 | ||||||
| MIC | 15.00 |
± 102.28 0.33 |
10.00 | 100.16 | 1.00 |
± 102.03 0.54 |
0.60 | 98.81 | |
| 15.00 | 99.37 | 0.80 | 98.16 | ||||||
| 25.00 | 98.45 | 1.00 | 98.36 | ||||||
| SD ± Mean | 0.86 ± 99.33 | SD ± Mean | 0.33 ± 98.44 | ||||||
aAverage of six experiments
bAverage of three experiments